CERO Stock Chart & Stats
$0.07
-$1.53(-29.25%)
At close: 4:00 PM EST
$0.07
-$1.53(-29.25%)
Day’s Range― - ―
52-Week Range<$0.01 - $8.95
Previous Close$3.66
Volume998.67K
Average Volume (3M)345.42K
Market Cap
$755.18K
Enterprise Value-$246.97K
Total Cash (Recent Filing)$857.49K
Total Debt (Recent Filing)$598.35K
Price to Earnings (P/E)―
Beta-0.45
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-73.31
Shares Outstanding45,112,408
10 Day Avg. Volume412,237
30 Day Avg. Volume345,415
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.05
Price to Sales (P/S)0.00
P/FCF Ratio-0.02
Enterprise Value/Market Cap-0.33
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.23
Enterprise Value/Ebitda0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.5
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Development ProgressThe Phase 1 dose-escalation study for CER-1236 moving into the next cohort indicates uninterrupted clinical advancement and continued evaluation in relapsed/refractory AML.
Clinical Safety ProfileNo safety issues reported so far with CER-1236 and one patient cleared for dose intensification, supporting a favorable early safety profile for the program.
Mechanism DifferentiationCER-1236's TIM-4–based design harnesses a natural immune/apoptosis pathway, creating a distinct approach that could reduce toxicities compared with traditional CAR-T therapies.
Bears Say
Analyst Rating And Market SentimentAnalyst downgrades to Hold following the NASDAQ delisting announcement reflect increased market uncertainty and negative sentiment toward the stock.
Listing And Capital Access RiskDelisting from NASDAQ raises concerns about liquidity and access to capital, which could complicate funding for ongoing clinical development.
CERo Therapeutics Holdings News
CERO FAQ
What was Cero Therapeutics Holdings, Inc.’s price range in the past 12 months?
Cero Therapeutics Holdings, Inc. lowest stock price was <$0.01 and its highest was $8.95 in the past 12 months.
What is Cero Therapeutics Holdings, Inc.’s market cap?
Cero Therapeutics Holdings, Inc.’s market cap is $755.18K.
When is Cero Therapeutics Holdings, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Cero Therapeutics Holdings, Inc.’s earnings last quarter?
Currently, no data Available
Is Cero Therapeutics Holdings, Inc. overvalued?
According to Wall Street analysts Cero Therapeutics Holdings, Inc.’s price is currently Overvalued.
Does Cero Therapeutics Holdings, Inc. pay dividends?
Cero Therapeutics Holdings, Inc. does not currently pay dividends.
What is Cero Therapeutics Holdings, Inc.’s EPS estimate?
Cero Therapeutics Holdings, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cero Therapeutics Holdings, Inc. have?
Cero Therapeutics Holdings, Inc. has 45,112,408 shares outstanding.
What happened to Cero Therapeutics Holdings, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cero Therapeutics Holdings, Inc.?
Currently, no hedge funds are holding shares in CERO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cero Therapeutics Holdings, Inc.
CERo Therapeutics Holdings, Inc. is a biotech firm dedicated to pioneering advanced engineered T-cell immunotherapies for the treatment of various cancers. Their leading therapeutic candidate, CER-1236, is an autologous T-cell therapy currently in development, aimed at addressing both blood cancers (hematologic malignancies) and solid tumors. This company was founded in 2021 and is headquartered in South San Francisco, California.
Technical Analysis
Theriva Biologics
―
GT Biopharma
―
Revelation Biosciences
―
Dermata Therapeutics
―
Psyence Biomedical
―
Ownership Overview
16.09%
Insiders
0.05% Other Institutional Investors
83.86% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---